PMID- 29165795
OWN - NLM
STAT- MEDLINE
DCOM- 20190415
LR  - 20220331
IS  - 1097-4652 (Electronic)
IS  - 0021-9541 (Linking)
VI  - 233
IP  - 6
DP  - 2018 Jun
TI  - Therapeutic potency of mTOR signaling pharmacological inhibitors in the treatment 
      of proinflammatory diseases, current status, and perspectives.
PG  - 4783-4790
LID - 10.1002/jcp.26276 [doi]
AB  - Mammalian target of rapamycin (mTOR) signaling pathway controls cell energy 
      metabolism. There is an interplay between mTOR and proinflammatory signaling 
      pathways, supporting the role of the pathway in the pathogenesis of inflammatory 
      diseases. Inhibition of mTOR signaling using specific pharmacological inhibitors 
      could offer therapeutic promise in several inflammatory-associated diseases. In 
      this review, we summarize recent findings on the regulatory effects of mTOR 
      signaling on inflammation and the therapeutic potency of mTOR pharmacological 
      inhibitors in the treatment of inflammatory diseases including cancer, 
      neurodegenerative diseases, atherosclerosis, sepsis, and rheumatoid arthritis for 
      a better understanding and hence a better management of these diseases.
CI  - (c) 2017 Wiley Periodicals, Inc.
FAU - Soltani, Arash
AU  - Soltani A
AD  - Faculty of Medicine, Department of Medical Biochemistry, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
AD  - Student Research Committee, Faculty of Medicine, Mashhad University of Medical 
      Sciences, Mashhad, Iran.
FAU - Bahreyni, Amirhossein
AU  - Bahreyni A
AD  - Department of Clinical Biochemistry and Immunogenetic Research Center, Faculty of 
      Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.
FAU - Boroumand, Nadia
AU  - Boroumand N
AD  - Faculty of Medicine, Department of Medical Biochemistry, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
FAU - Roshan, Mostafa Karimi
AU  - Roshan MK
AD  - Faculty of Medicine, Department of Medical Biochemistry, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
FAU - Khazaei, Majid
AU  - Khazaei M
AUID- ORCID: 0000-0002-7979-5699
AD  - Faculty of Medicine, Department of Medical Physiology, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
FAU - Ryzhikov, Mikhail
AU  - Ryzhikov M
AD  - Department of Molecular Microbiology and Immunology, St. Louis University, School 
      of Medicine, Saint Louis, Missouri.
FAU - Soleimanpour, Saman
AU  - Soleimanpour S
AD  - Department of Microbiology and Virology, School of Medicine, Mashhad University 
      of Medical Sciences, Mashhad, Iran.
FAU - Avan, Amir
AU  - Avan A
AUID- ORCID: 0000-0002-4968-0962
AD  - Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Faculty of Medicine, Department of Modern Sciences and Technologies, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
FAU - Hassanian, Seyed Mahdi
AU  - Hassanian SM
AUID- ORCID: 0000-0002-5247-4043
AD  - Faculty of Medicine, Department of Medical Biochemistry, Mashhad University of 
      Medical Sciences, Mashhad, Iran.
AD  - Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, 
      Mashhad, Iran.
AD  - Faculty of Medicine, Department of Modern Sciences and Technologies, Mashhad 
      University of Medical Sciences, Mashhad, Iran.
AD  - Microanatomy Research Center, Mashhad University of Medical Sciences, Mashhad, 
      Iran.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20171226
PL  - United States
TA  - J Cell Physiol
JT  - Journal of cellular physiology
JID - 0050222
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Protein Kinase Inhibitors)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/drug therapy/enzymology/immunology
MH  - Atherosclerosis/drug therapy/enzymology/immunology
MH  - Humans
MH  - Inflammation/*drug therapy/enzymology/immunology
MH  - Inflammation Mediators/*antagonists & inhibitors/immunology/metabolism
MH  - Molecular Targeted Therapy
MH  - Neoplasms/drug therapy/enzymology/immunology
MH  - Neurodegenerative Diseases/drug therapy/enzymology/immunology
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Sepsis/drug therapy/enzymology/immunology
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors/immunology/metabolism
OTO - NOTNLM
OT  - inflamatory diseases
OT  - inflammation
OT  - mammalian target of rapamycin
OT  - pharmacological inhibitors
EDAT- 2017/11/23 06:00
MHDA- 2019/04/16 06:00
CRDT- 2017/11/23 06:00
PHST- 2017/07/31 00:00 [received]
PHST- 2017/10/14 00:00 [revised]
PHST- 2017/11/14 00:00 [accepted]
PHST- 2017/11/23 06:00 [pubmed]
PHST- 2019/04/16 06:00 [medline]
PHST- 2017/11/23 06:00 [entrez]
AID - 10.1002/jcp.26276 [doi]
PST - ppublish
SO  - J Cell Physiol. 2018 Jun;233(6):4783-4790. doi: 10.1002/jcp.26276. Epub 2017 Dec 
      26.